Adenosine Agonist for Stress Perfusion Imaging Approved

April 15, 2008

April 15, 2008 (Palo Alto, CA and Deerfield, IL) - The US Food and Drug Administration has market-approved regadenoson (Lexiscan), a selective A2A adenosine-receptor agonist, for resting stress-myocardial perfusion scans, the product's developer and owner CV Therapeutics and marketer-distributor Astellas Pharma US have jointly announced [1].

Lexiscan was approved based on two identical phase 3 trials [2] in which the agent produced perfusion scans of similar quality to those made using another Astellas product, adenosine injection (Adenoscan), according to the announcement. Lexiscan is administered as a non–weight-adjusted rapid bolus, which, published reports observe, is a less complicated regimen than what is required for adenosine; it's also expected to have a more favorable side-effect profile by virtue of its adenosine-receptor selectivity.

  1. CV Therapeutics. CV Therapeutics and Astellas announce FDA approval for Lexiscan (regadenoson) injection [press release]. April 10, 2008. Available at: .

  2. Iskandrian AE, Bateman TM, Belardinelli L, et al. ADVANCE MPI Investigators. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007; 14:645-658. Abstract

The complete contents of Heartwire , a professional news service of WebMD, can be found at, a Web site for cardiovascular healthcare professionals.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.